European Medicines Agency accepts submission of Marketing Authorisation Application for niraparib as first-line maintenance treatment of ovarian cancer

The submission was based on data from the placebo-controlled Phase III PRIMA clinical study, which reported statistically significant improvements in progression-free survival. Niraparib is currently only licensed for use as a maintenance treatment in relapsed disease.


Biospace Inc.